Filtered By:
Condition: Bleeding
Drug: Coumadin
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 1962 results found since Jan 2013.
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population: updated analysis
CONCLUSIONS: This real-world analysis showed DOACs to be associated with lower risk of stroke/SE and major bleeding, and lower medical costs compared to warfarin. Among them, only apixaban appears to be associated with a significantly lower risk of all three outcomes collectively: stroke/SE, major bleeding, and lower related medical costs compared to warfarin.PMID:35993487 | DOI:10.1080/03007995.2022.2115772
Source: Current Medical Research and Opinion - August 22, 2022 Category: Research Authors: Alpesh Amin Allison Keshishian Dionne M Hines Oluwaseyi Dina Hannah Le Lisa Rosenblatt Xianchen Liu Qisu Zhang Lien Vo Source Type: research
Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry
ConclusionsIn a real-world cohort of AF patients on edoxaban, diabetes requiring insulin therapy, rather than the presence of diabetes per se, appears to be an independent factor affecting the occurrence of thromboembolic events during follow-up. Regardless of the diabetes type, diabetic patients had a lower survival compared with those without diabetes.Graphical abstract
Source: Clinical Research in Cardiology - August 17, 2022 Category: Cardiology Source Type: research
Apixaban for Anticoagulation after Robotic Mitral Valve Repair
CONCLUSIONS: Anticoagulation with apixaban after minimally invasive robotic MVRep is safe and has similar rates of bleeding and thromboembolism compared to patients treated with warfarin.PMID:35973484 | DOI:10.1016/j.athoracsur.2022.07.045
Source: The Annals of Thoracic Surgery - August 16, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Piotr K Mazur Arman Arghami Shea A Macielak Scott D Nei Jason K Viehman Katherine S King Richard C Daly Juan A Crestanello Hartzell V Schaff Joseph A Dearani Source Type: research
Bleeding events in the emergency department with warfarin versus novel oral anticoagulants: A five-year analysis
Conclusion: Our findings indicate that rates of major and minor bleeding complications in patients taking NOACs are similar to those in patients taking warfarin. While warfarin was associated with fewer complications than NOACs in terms of gastrointestinal bleeding, the risk of intracranial bleeding, was similar between the groups.
Source: Nigerian Journal of Clinical Practice - August 16, 2022 Category: Rural Health Authors: Y Dogan A Az O Sogut T Akdemir O Kaplan Source Type: research
Direct oral anticoagulants versus warfarin in patients with antiphospholipid syndrome: A meta-analysis of randomized controlled trials
CONCLUSION: DOACs were associated with higher rates of arterial thrombosis than warfarin in patients with APS, especially in the triple-positive group. However, a higher risk of recurrent venous thrombosis was not found in APS patients treated with DOACs compared to those treated with warfarin.PMID:35968627 | DOI:10.1177/09612033221118463
Source: Lupus - August 15, 2022 Category: Rheumatology Authors: Young H Lee Gwan G Song Source Type: research
Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis
CONCLUSION: Although LAAO could be an alternative to anticoagulants for stroke prevention in patients with AF and high bleeding risk, the overall benefit from LAAO depends on the combination of stroke and bleeding risks in individual patients. These results suggest the need for a sufficiently low stroke risk for LAAO to be beneficial. The authors believe that these results could improve shared decision making when selecting patients for LAAO.PRIMARY FUNDING SOURCE: None.PMID:35969865 | DOI:10.7326/M21-4653
Source: Annals of Internal Medicine - August 15, 2022 Category: Internal Medicine Authors: Derek S Chew Ke Zhou Sean D Pokorney David B Matchar Sreekanth Vemulapalli Larry A Allen Kevin P Jackson Zainab Samad Manesh R Patel James V Freeman Jonathan P Piccini Source Type: research
Direct oral anticoagulants versus warfarin in patients with antiphospholipid syndrome: A meta-analysis of randomized controlled trials
CONCLUSION: DOACs were associated with higher rates of arterial thrombosis than warfarin in patients with APS, especially in the triple-positive group. However, a higher risk of recurrent venous thrombosis was not found in APS patients treated with DOACs compared to those treated with warfarin.PMID:35968627 | DOI:10.1177/09612033221118463
Source: Lupus - August 15, 2022 Category: Rheumatology Authors: Young H Lee Gwan G Song Source Type: research
